National Academies Press: OpenBook
« Previous: Implementing a National Cancer Clinical Trials System for the 21st Century
Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

References

Abrams, J., R. Erwin, G. Fyfe, R. L. Schilsky, and R. Temple. 2009. Data submission standards and evidence requirements. Presented at the Conference on Clinical Cancer Research, Panel 1. Engelberg Center for Health Care Reform, Brookings Institution, Washington, DC.

Abrams, J. S., M. M. Mooney, J. A. Zwiebel, E. L. Korn, S. H. Friedman, S. R. Finnigan, P. R. Schettino, A. M. Denicoff, M. G. Kruhm, M. Montello, R. R. Misra, S. S. Ansher, K. J. Dipiazza, E. M. Souhan, D. L. Wickerham, B. J. Giantonio, R. T. O’Donnell, D. M. Sullivan, N. I. Soto, G. F. Fleming, S. A. Prindiville, R. A. Petryshyn, J. A. Hautala, O. Grad, B. L. Zuckerman, R. M. Meyer, J. C. Yao, L. A. Baker, J. C. Buckner, G. N. Hortobagyi, and J. H. Doroshow. 2013. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. Journal of the National Cancer Institute 105(13):947-953.

Amit, O., F. Mannino, A. M. Stone, W. Bushnell, J. Denne, J. Helterbrand, and H. U. Burger. 2011. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis. European Journal of Cancer 47(12):1772-1778.

Burstein, H. J. 2011. Bevacizumab for advanced breast cancer: All tied up with a ribbon? Journal of Clinical Oncology 29(10):1232-1235.

Califf, R. M., D. A. Zarin, J. M. Kramer, R. E. Sherman, L. H. Aberle, and A. Tasneem. 2012. Characteristics of clinical trials registered in clinicaltrials.Gov, 2007-2010. Journal of the American Medical Association 307(17):1838-1847.

CFF (Cystic Fibrosis Foundation). 2012. Kalydecohttp://www.cff.org/treatments/therapies/kalydeco (accessed May 9, 2013).

Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

Cortazar, P., L. Zhang, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, J. Zujewski, R. Justice, S. Loibl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, T. Prowell, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. Fasching, S. Swain, L. Slaets, S. Tang, B. Gerber, C. Geyer, R. Pazdur, N. Ditsch, P. Rastogi, W. Eiermann, and G. von Mincwitz. 2012. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNEOBC). Paper presented at San Antonio Breast Cancer Symposium, San Antonio, TX, December 5.

Dodd, L. E., E. L. Korn, B. Freidlin, C. C. Jaffe, L. V. Rubinstein, J. Dancey, and M. M. Mooney. 2008. Blinded independent central review of progression-free survival in phase III clinical trials: Important design element or unnecessary expense? Journal of Clinical Oncology 26(22):3791-3796.

Eichler, H. G., K. Oye, L. G. Baird, E. Abadie, J. Brown, C. L. Drum, J. Ferguson, S. Garner, P. Honig, M. Hukkelhoven, J. C. Lim, R. Lim, M. M. Lumpkin, G. Neil, B. O’Rourke, E. Pezalla, D. Shoda, V. Seyfert-Margolis, E. V. Sigal, J. Sobotka, D. Tan, T. F. Unger, and G. Hirsch. 2012. Adaptive licensing: Taking the next step in the evolution of drug approval. Clinical Pharmacology and Therapeutics 91(3):426-437.

EMA (European Medicines Agency). 2010. Questions and answers on the review of avastin (bevacizumab) in the treatment of metastatic breast cancer. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/12/WC500099939.pdf (accessed May 16, 2013).

FDA (Food and Drug Administration). 2006. Information sheet guidance for IRBs, clinical investigators, and sponsors: Significant risk and nonsignificant risk medical device studies. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126418.pdf (accessed May 9, 2013).

———. 2012a. Draft guidance for industry and FDA staff. Medical devices: The pre-submission program and meetings with FDA staff. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm310375.htm (accessed May 9, 2013).

———. 2012b. FDA briefing document. Oncologic drugs advisory committee meeting. July 24, 2012. Evaluation of radiologic review of progression-free survival in non-hematologic malignancies. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM311141.pdf (accessed May 9, 2013).

———. 2012c. Guidance for industry on determining the extent of safety data collection needed in late stage premarket and postapproval clinical investigations. https://s3.amazonaws.com/public-inspection.federalregister.gov/2012-03096.pdf (accessed May 9, 2013).

———. 2012d. Guidance for IRBs, clinical investigators and sponsors: IRB responsibilities for reviewing the qualifications of investigators, adequacy of research sites, and the determination of whether an IND/IDE is needed. http://www.fda.gov/RegulatoryInformation/Guidances/ucm366335.htm (accessed May 9, 2013).

———. 2012e. Kalydeco (ivacaftor) information. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm323671.htm (accessed May 9, 2013).

Freidlin, B., L. M. McShane, and E. L. Korn. 2010. Randomized clinical trials with biomarkers: Design issues. Journal of the National Cancer Institute 102(3):152-160.

Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

Hamburg, M. 2010. Drug regulation in the modern era. 11th Annual HBS Industry Alumni Association Conference. November 5, 2010, Boston, MA.

Hirsch, B. R., R. M. Califf, S. K. Cheng, A. Tasneem, J. Horton, K. Chiswell, K. A. Schulman, D. M. Dilts, and A. P. Abernethy. 2013. Characteristics of oncology clinical trials: Insights from a systematic analysis of ClinicalTrials.gov. JAMA Internal Medicine 173(11):972-979.

IOM (Institute of Medicine). 2010a. A foundation for evidence-driven practice: A rapid learning system for cancer care: Workshop summary. Washington, DC: The National Academies Press.

———. 2010b. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program. Washington, DC: The National Academies Press.

———. 2011. Implementing a national cancer clinical trials system for the 21st century: Workshop summary. Washington, DC: The National Academies Press.

Kaiser, J. 2013. Rare cancer successes spawn “exceptional” research efforts. Science 340(6130):263.

Kaitin, K. I., and J. A. DiMasi. 2011. Pharmaceutical innovation in the 21st century: New drug approvals in the first decade, 2000-2009. Clinical Pharmacology and Therapeutics 89(2):183-188.

National Human Genome Research Institute. 2013. Clinical Sequencing Exploratory Research (CSER). http://www.genome.gov/27546194 (accessed May 30, 2013).

NCI (National Cancer Institute). 2012. NCI Office of Cancer Centers (OCC) learning series. An overview of the NCI’s Community Oncology Research Program. http://cancercenters.cancer.gov/Webinar/NCORP/NCORPwebinar.html (accessed May 9, 2013).

NCI and CEO Roundtable on Cancer. 2008. Proposed standardized/harmonized clauses for clinical trial agreement. http://transformingtrials.cancer.gov/files/StClauses.pdf (accessed May 9, 2013).

Stephens, P. J., P. S. Tarpey, H. Davies, P. Van Loo, C. Greenman, D. C. Wedge, S. Nik-Zainal, S. Martin, I. Varela, G. R. Bignell, L. R. Yates, E. Papaemmanuil, D. Beare, A. Butler, A. Cheverton, J. Gamble, J. Hinton, M. Jia, A. Jayakumar, D. Jones, C. Latimer, K. W. Lau, S. McLaren, D. J. McBride, A. Menzies, L. Mudie, K. Raine, R. Rad, M. S. Chapman, J. Teague, D. Easton, A. Langerod, M. T. Lee, C. Y. Shen, B. T. Tee, B. W. Huimin, A. Broeks, A. C. Vargas, G. Turashvili, J. Martens, A. Fatima, P. Miron, S. F. Chin, G. Thomas, S. Boyault, O. Mariani, S. R. Lakhani, M. van de Vijver, L. van’t Veer, J. Foekens, C. Desmedt, C. Sotiriou, A. Tutt, C. Caldas, J. S. Reis-Filho, S. A. Aparicio, A. V. Salomon, A. L. Borresen-Dale, A. L. Richardson, P. J. Campbell, P. A. Futreal, and M. R. Stratton. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486(7403):400-404.

Trotta, F., H. G. Leufkens, J. H. Schellens, R. Laing, and G. Tafuri. 2011. Evaluation of oncology drugs at the European Medicines Agency and U.S. Food and Drug Administration: When differences have an impact on clinical practice. Journal of Clinical Oncology 29(16):2266-2272.

Yelensky, R., G. M. Frampton, A. Fichtenholtz, S. Downing, J. He, F. Juhn, K. Brennan, K. Wang, G. Otto, M. Jarosz, A. Parker, J. S. Ross, J. Curran, M. T. Cronin, P. J. Stephens, and D. Lipson. 2013. Bringing next generation sequencing (NGS) to the clinic: Analytical validation of a comprehensive NGS-based cancer gene test. Paper presented at AACR Annual Meeting 2013, Washington, DC, April 8.

Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×

Zhang, J. J., H. Chen, K. He, S. Tang, R. Justice, P. Keegan, R. Pazdur, and R. Sridhara. 2013. Evaluation of blinded independent central review of tumor progression in oncology clinical trials: A meta-analysis. Therapeutic Innovation and Regulatory Science 47(2):167-174.

Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 75
Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 76
Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 77
Suggested Citation:"References." Institute of Medicine. 2013. Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18362.
×
Page 78
Next: Acronyms »
Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary Get This Book
×
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The National Clinical Trials Network (NCTN) supported by the National Cancer Institute (NCI) has played an integral role in cancer research and in establishing the standard of care for cancer patients for more than 50 years. Formerly known as the NCI Clinical Trials Cooperative Group Program, the NCTN is comprised of more than 2,100 institutions and 14,000 investigators, who enroll more than 20,000 cancer patients in clinical trials each year across the United States and internationally.

Recognizing the recent transformative advances in cancer research that necessitate modernization in how cancer clinical trials are run, as well as inefficiencies and other challenges impeding the national cancer clinical trials program, the NCI asked the IOM to develop a set of recommendations to improve the federally funded cancer clinical trials system. These recommendations were published in the 2010 report, A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program.
In early 2011, the NCPF and the American Society of Clinical Oncology (ASCO) held a workshop in which stakeholders discussed the changes they planned to implement in response to the IOM goals and recommendations. Two years later, on February 11-12, 2013, in Washington, DC, the NCPF and ASCO reconvened stakeholders to report on the changes they have made thus far to address the IOM recommendations. At this workshop, representatives from the NCI, the NCTN, comprehensive cancer centers, patient advocacy groups, the Food and Drug Administration (FDA), industry, and other stakeholders highlighted the progress that has been made in achieving the goals for a reinvigorated national cancer clinical trials system. Implementing a National Cancer Clinical Trials System for the 21st Century is a summary of that workshop.
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!